47 research outputs found

    The impact of boundary layer height on air pollution concentrations in London – early results from the ClearfLo project.

    Get PDF
    The ClearfLo projects aims to understand the processes generating pollutants like ozone, NOx and particulate matter and their interaction with the urban atmospheric boundary layer. ClearfLo (www.clearflo.ac.uk) is a large multi-institution NERC-funded project that is establishing integrated measurements of the meteorology, composition and particulate loading of London’s urban atmosphere, complemented by an ambitious modeling programme. The project established a new long-term measurement infrastructure in London encompassing measurement capabilities at street level and at elevated sites. These measurements were accompanied by high resolution mod- eling with the UK Met Office Unified model and WRF. This combined measuring/modelling approach enables us to identify the seasonal cycle in the meteorology and composition, together with the controlling processes. Two intensive observation periods in January/February 2012 and during the Olympics in summer 2012 measured London’s atmosphere with higher level of detail. Data from these IOPs will enable us (i) to determine the vertical structure and evolution of the urban atmosphere (ii) to determine the chemical controls on ozone production, particularly the role of biogenic emissions and (iii) to determine the processes controlling the evolution of the size,distribution and composition of particulate matter. We present results from the wintertime IOP in London focusing on a wintertime pollution episode during January 2012. We compare measured concentrations from top of BT Tower in central London with rural background measurements and determine the processes leading to the urban increment in pollutant concentrations. Therefore, we combine high-resolution simulations with the Met Office Unified Model for London and mixing layer heights derived from lidar measurements with air quality measurements in central London in order to quantify the role the boundary layer depth plays for London’s concentrations

    Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

    Get PDF
    Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

    Turbulent boundary layer flow over undulating surfaces

    No full text
    SIGLEAvailable from British Library Document Supply Centre- DSC:D60148 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

    Effects of swell on the growth of wind waves

    No full text
    International audienc

    Effets of swell on wind-wave generation

    No full text
    International audienc

    Effects of airflow on modulation of short surface waves by long waves

    No full text
    International audienc
    corecore